The company has not filed an annual or quarterly report since its Q1 FY2017 10-Q, filed May 10, 2017. Its latest SEC filing is a SC 13G/A from Feb 14, 2018.
10-Q for Q1 FY2017, filed May 10, 2017
The sections below describe the company as of the latest annual report.
Develops and sells collagen-based surgical products, including implants, sponges and films that break down in the body, through healthcare companies that market and distribute them.
10-K, filed Mar 16, 2017We are a global, commercial stage specialty pharmaceutical and medical device company with late stage development programs targeting areas…View ↗
Our lead product candidate is XaraColl® for the treatment of post-operative pain. We initiated our Phase 3 trials for XaraColl in the third…View ↗
As of December 31, 2016, we had four marketed products: (i) CollaGUARD, which utilizes our CollaFilm® technology, a transparent…View ↗
All of our marketed products are currently sold by commercial partners. CollatampG has been marketed outside of the United States since…View ↗
All marketed products are sold through commercial partners. EUSA Pharma distributes CollatampG outside the United States; Biomet and Biomet 3i receive Septocoll and RegenePro for distribution, and partners distribute CollaGUARD in some approved territories.
10-K, filed Mar 16, 2017Our lead product candidate is XaraColl® for the treatment of post-operative pain. We initiated our Phase 3 trials for XaraColl in the third…View ↗
All of our marketed products are currently sold by commercial partners. CollatampG has been marketed outside of the United States since…View ↗
Europe and the Middle East. CollaGUARD has been approved in 12 countries within Asia, Europe, Latin America and the Middle East. RegenePro…View ↗
10-K, filed Mar 16, 2017
The majority of product revenue in 2016, $4.2 million, relates to sales of CollatampG and Septocoll and is split between two customers…View ↗
10-Q for Q1 FY2017, filed May 10, 2017
−$12.7MView ↗
8-K, filed Jul 24, 2017
On July 24, 2017, pursuant to the terms of the Transaction Agreement, Gurnet Bidco acquired Innocoll by means of a scheme of arrangement…View ↗
8-K, filed May 3, 2017
On May 1, 2017, Jose Carmona notified the Company that he will resign from his position as Chief Financial Officer of the Company. Mr.…View ↗
Loading...
